Neuroscience & Mental Health
Other Therapeutic Program Areas
Three outstanding mid-career researchers and new ARC Future Fellows, Associate Professor Darren Creek, Dr Nicholas Veldhuis and Dr Roey Elnathan have received close to $3M in funding to advance research projects addressing a range of medical needs.
A new start-up company led by researchers at The Australian National University and Monash University has received funding to develop a method to block inflammation caused by a number of common diseases, including cardiovascular disease,
A new Monash biotech company called Phrenix Therapeutics has received funding to advance research to develop new therapeutics for cognitive disorders, particularly in schizophrenia.
Monash University researchers have conducted a review into the prevalence of depression and anxiety of people with cystic fibrosis, a life-limiting genetic disease associated with high levels of psychological burden.
A drug delivery platform developed by Monash University researchers in partnership with PureTech Health plc has shown for the first time in humans that a drug that currently must be injected due to breakdown in the liver after oral administration,
Development of the Guidelines were led by Centre for Medicine Use and Safety, with funding from the National Health and Medical Research Council Dementia Centre for Research Collaboration in response to recommendations from the recent Royal
Monash University researchers have harnessed a new drug delivery technology to allow the oral administration of buprenorphine (BUP), a drug used for severe pain management and opioid replacement therapy. At present BUP cannot be administered in a
Monash University scientists have discovered the structure of the protein behind neurofibromatosis type 1 (NF1), a common genetic condition that causes tumours to form on nerve tissue.